

Revmatologie

- 2 **Současný pohled na aplikaci glukokortikoidů současně s DMARDs u revmatoidní artritidy**
prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha
- 2 **Glukokortikoidy u systémového lupus erythematoses a možnosti tzv. kortikoidy šetřících terapeutických režimů** MUDr. Hana Ciferská, Ph.D. | MUDr. Dana Tegzová Revmatologický ústav, Praha, a Revmatologická klinika 1. LF UK, Praha MUDr. Jan Vachek Klinika nefrologie, VFN a 1. LF UK, Praha
- 3 **Glukokortikoidy indukovaná osteoporóza, možnosti prevence a léčby**
prof. MUDr. Jan Štěpán, DrSc. Revmatologický ústav a 1. LF UK, Praha
- 3 **Glukokortikoidy v léčbě idiopatických zánětlivých myopatií**
MUDr. Heřman Mann Revmatologický ústav a Klinika revmatologie 1. LF UK, Praha
- 4 **Glukokortikoidy v intraartikulární léčbě u zánětlivých revmatických onemocnění**
MUDr. Radka Svobodová Revmatologický ústav, Praha
- 5 **Nežádoucí účinky glukokortikoidů u autoimunitních onemocnění**
MUDr. Šárka Forejtová Revmatologický ústav, Praha
- 5 **Golimumab v kombinované léčbě aktivní revmatoidní artritidy v širší klinické praxi**
prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha
- 6 **Výsledky léčby abataceptem hodnocené dle ACR-EULAR kritérií**
prof. Ing. Jaroslav Petr, DrSc. Praha
- 6 **Komentář k článku: Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept—treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE).**
prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha
- 6 **Febuxostat šetří funkci ledvin u dny**
MUDr. Lenka Petrů | MUDr. Jakub Závada Ph.D. Revmatologický ústav, Praha
- 7 **Co je cílem léčby revmatoidní artritidy?**
MUDr. Heřman Mann Revmatologický ústav a Klinika revmatologie 1. LF UK, Praha
- 7 **Význam subkutánního metotrexátu v léčbě revmatických onemocnění**
doc. MUDr. Radim Bečvář, CSc. Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha
- 7 **Postavení kanakinumabu v léčbě akutní dny**
MUDr. Jakub Závada, Ph.D. Revmatologický ústav, Praha
- 8 **Vliv tocilizumabu na příznaky deprese u nemocných s revmatoidní artritidou**
MUDr. Heřman Mann Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha
- 8 **Imunogenicitu inhibitorů TNF α – zaměřeno na etanercept**
MUDr. Hana Ciferská, Ph.D. | MUDr. Monika Urbanová | MUDr. Liliana Šedová
Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha
- 8 **Bolest u osteoartrózy kolene dospělých – novinky v léčbě**
Mgr. Dana Frantálová
- 9 **Stroncium ranelát – efektivní možnost léčby osteoporózy**
prof. MUDr. Juraj Payer, PhD., MPH, FRCP | MUDr. Peter Jackuliak, PhD. | MUDr. Kristína Brázdilová, PhD.
V. interná klinika Lékařské fakulty UK a UN, Bratislava
- 9 **Co můžeme udělat pro pacienta s psoriatickou artritidou, když selžou inhibitory TNF α ?**
MUDr. Jiří Štolfa Revmatologický ústav, Praha
- 9 **Revmatologické projevy u pacientů s mukopolysacharidózou**
MUDr. RNDr. Pavel Ješina, Ph.D. Ústav dědičných metabolických poruch 1. LF UK a VFN, Praha

Současný pohled na aplikaci glukokortikoidů současně s DMARDs u revmatoidní artritidy

prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha

- Hench, P.: Effects of cortisone in rheumatic diseases. *Lancet*, 1950, 2, s. 483–484.
- Jacobs, J. – Bijlsma, J.: Glucocorticoid therapy. In: Firestein, S. – Budd, R. – Gabriel, S., et al. (eds.): *Kelley's Textbook of Rheumatology*. Elsevier, 9. vydání, Philadelphia, s. 894–916.
- Boumpas, D. – Chrousos, G. P. – Wilder, R. L., et al.: Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. *An Intern Med*, 1993, 119, s. 1198–1208.
- Huscher, D., et al.: Dose-related patterns of glucocorticoid-induced side effects. *Ann Rheum Dis*, 2009, 68, s. 1119–1124.
- Wolfe, F. – Caplan, L. – Michaud, K., et al.: Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease modifying antirheumatic drugs and anti tumour necrosis factor therapy. *Arthritis Rheum*, 2006, 54, s. 628–634.
- Kalla, A. – Tikly, M.: Rheumatoid arthritis in the developing world. *Best Pract Res Clin Rheumatol*, 2003, 17, s. 863–875.
- Smolen, J. S. – Aletaha, D. – Bijlsma, J. W., et al.: Treating rheumatoid arthritis to target. Recommendation of an international task force. *Ann Rheum Dis*, 2010, 69, s. 631–637.
- Pavelka, K. jr. – Honzlová, M. – Vencovský J.: Aplikace pulzní steroidní léčby u aktivní revmatoidní artritidy. *Cas Lék Čes*, 1992, 19, s. 593–599.
- Hetland, M. L. – Horslev-Petersen, K.: The CIMESTRA study: intra-articular glucocorticoids and synthetic DMARDs in a treat-to target strategy in early rheumatoid arthritis. *Clin Exp Rheumatol*, 2012, 30, s. 44–49.
- Smolen, J. S. – Landewe, R. – Breedveld, F. C., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease modifying antirheumatic drugs: 2013 update. *Ann Rheum Dis*, 2013, 73, s. 492–509.
- Gorter, S. L. – Bijlsma, J. – Cutolo, M., et al.: Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. *Ann Rheum Dis*, 2010, 69, s. 1010–1014.
- Bakker, M. F. – Jacobs, J. W. C. – Welsing, P., et al.: Low-dose prednisone in a methotrexate – based, tight control strategy for early RA. *Ann Intern Med*, 2012, 156, s. 329–339.
- Landawe, R. – Boers, M. – Verhoven, A. C., et al.: COBRA combination therapy with early rheumatoid arthritis long term structural benefits of a brief intervention. *Arthritis Rheum*, 2002, 46, s. 347–356.
- Verschuren, P. – Cock, D. – Corluy, L., et al.: Methotrexate with other DMARDs not superior to MTX alone for remission induction with moderate- to high glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment? The CareRA trial. *Ann Rheum Dis*, 2015, 74, s. 27–34.
- Wassenberg, S. – Rau, R. – Steinfeld, P., et al.: Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years. *Arthritis Rheum*, 2005, 52, s. 3371–3380.
- Choy, E. H. – Kingsley, G. H. – Khoshaba, B., et al.: Intramuscular methylprednisolone study group. A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs. *Ann Rheum Dis*, 2005, 64, s. 1288–1293.
- Cappel, H. A. – Madhok, R. – Hunter, J. A., et al.: Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis. Results of a randomised controlled trial. *Ann Rheum Dis*, 2004, 63, s. 797–803.
- Hanssen, M. – Podenphant, J. – Florescu, A., et al.: A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effects. *Ann Rheum Dis*, 1999, 58, s. 713–718.
- Goekoop-Ruiterman, Y. P. – de Vries Boustra, K. – Allart, C. E., et al.: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the Best study) a randomized, controlled trial. *Arthritis Rheum*, 2005, 52, s. 3381–3390.
- Mottonen, T. – Hannonen, P. – Leirisalo-Repo, M., et al.: Comparison of combination therapy with single drug therapy in early rheumatoid arthritis: a randomized trial. FIN-RACO trial group. *Lancet*, 1999, 353, s. 1568–1573.
- Kirwan, J. R. – Bijlsma, J. W. J. – Boers, M.: Effects of glucocorticoids on radiological progression in rheumatoid arthritis. *Cochrane Database Syst Rev*, online, 2007, 1, CD006356.
- Criswell, L. A. – Saag, K. G. – Sems, K. M., et al.: Moderate term, low dose corticosteroids for rheumatoid arthritis. *Cochrane Database Syst Rev*, online, 2000, 2, CD001158.
- De Silva, M. – Binder, A. – Hazleman, B. L.: The timing of prednisolone dosage and its effect on morning stiffness in rheumatoid arthritis. *Ann Rheum Dis*, 1984, 43, s. 790–793.
- Arvidsson, N. G. – Gudbjornsson, B. – Larsson, A.: The timing of glucocorticoid administration in rheumatoid arthritis. *Ann Rheum Dis*, 1997, 56, s. 27–31.
- Buttgereit, F. – Doering, G. – Shaeffeler, A.: Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1) a double blind, randomised trial. *Lancet*, 2008, 371, s. 205–214.
- van Gestl, A. M. – Laan, R. F. – Haagsma, C. J., et al.: Oral steroids as bridge therapy in rheumatoid arthritis patients starting with parenteral gold. A randomized double blind placebo controlled trial. *Br J Rheumatol*, 1995, 34, s. 347–351.
- Goetsche, P. C. – Joghansen, H. K.: Short-term low-dose corticosteroids vs placebo and nonsteroidal anti-inflammatory drugs in rheumatoid arthritis. *Cochrane Database Syst Rev*, 2005, 1, CD000189.

Glukokortikoidy u systémového lupus erythematoses a možnosti tzv. kortikoidy šetřících terapeutických režimů

MUDr. Hana Ciferská, Ph.D. | MUDr. Dana Tegzová

Revmatologický ústav, Praha, a Revmatologická klinika 1. LF UK, Praha

MUDr. Jan Vachek Klinika nefrologie, VFN a 1. LF UK, Praha

- Domic, R. T. – Ramsey-Goldman, R. – Manzi, S.: Epidemiology and classification of systemic lupus erythematosus. *Rheumatology*. Philadelphia (PA), Mosby-Elsevier, 2008, s. 1211–1216.
- Hochberg, M. C., et al.: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum*, 1997, 40, s. 1725.
- Hochberg, M. C. – Silman, A. J. – Smolen, J. S. – Weinblatt, M. E. – Weisman, M.: Epidemiology and classification of systemic lupus erythematosus. *Rheumatology*. Philadelphia (PA), Mosby-Elsevier, 2008, s. 1211–1216.
- Stahn, C. – Buttgereit, F.: Genomic and nongenomic effects of glucocorticoids. *Nat Clin Pract Rheumatol*, 2008, 4, s. 525–533.
- Rhen, T. – Cidlowski, J. A.: Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. *N Engl J Med*, 2005, 353, s. 1711–1723.
- van Vollenhoven, R. F. – Mosca, M. – Bertisias, G., et al.: Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. *Ann Rheum Dis*, 2014, 73, s. 958–967.
- Horák, P. – Tezová, D. – Závada, Z., et al.: Doporučení ČRS pro léčbu nemocných se SLE. *Čes Revmatol*, 2013, 21, s. 110–122.
- Gladman, D. D. – Urowitz, M. B. – Rahman, P., et al.: Accrual of organ damage over time in patients with systemic lupus erythematosus. *J Rheumatol*, 2003, 30, s. 1955–1959.
- Hamer, M. – Hernán, M. A. – Zhang, Y. – Cotter, D. – Petri, M.: Prednisone, lupus activity, and permanent organ damage. *J Rheumatol*, 2009, 36, s. 560–564.
- Carneiro, J. R. – Sato, E. I. J.: Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. *Rheumatol*, 1999, 26, s. 1275–1279.
- Fortin, P. R. – Abrahamowicz, M. – Ferland, D., et al.: Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. *Arthritis Rheum*, 2008, 59, s. 1796–1804.
- Baker, K. P. – Edwards, B. M. – Main, S. H., et al.: Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. *Arthritis Rheum*, 2003, 48, s. 3253–3265.
- Human Genome Science BENLYSTA™ (belimumab), dostupné z: www.hgsi.com/belimumab.html.
- van Vollenhoven, R. F. – Gallacher, A. – Navarra, S., et al.: Belimumab, a BlyS-Specific Inhibitor, Reduced Corticosteroid Use in Patients with Active SLE: Results from the Phase 3 BLISS-52 and -76 Studies. [abstract]. *Arthritis Rheum*, 2010, 62 (dopl. 10), s. 451.
- Petri, M. – Levy, R. A. – Merrill, J. T., et al.: Belimumab, a BlyS-specific inhibitor, reduced disease activity, flares, and prednisone use in patients with seropositive SLE: combined efficacy results from the phase 3 BLISS-52 and -76 studies. *Arthritis Rheum*, 2010, 62 (dopl. 10), s. 190.
- Cervera, R. – Furie, R. – Levy, R., et al.: Relationship of belimumab treatment response with corticoid use and severe flares in patients with SLE: BLISS-52 and BLISS-76. *Ann Rheum Dis*, 2011, 70 (dopl. 3), s. 321.
- Navarra, S. V. – Guzmán, R. M. – Gallacher, A. E., et al.: BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. *Lancet*, 2011, 26, 377, s. 721–731.
- Furie, R. – Petri, M. – Zamani, O. – Cervera, R., et al.: BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. *Arthritis Rheum*, 2011, 63, s. 3918–3930.
- Navarra, S. – Ilianova, E. – Bae, S. C., et al.: Belimumab, a BlyS-specific inhibitor, reduced disease activity, flares, and steroid use in patients with seropositive systemic lupus erythematosus (SLE): BLISS-52 study. *Ann Rheum Dis*, 2010, 69 (dopl. 3), s. 556.
- Collins, C. E. – Oglesby, M. – McGuire, A., et al.: 12-Month Outcomes Associated With Belimumab In Patients With Systemic Lupus Erythematosus In Clinical Practice Settings: The Observe Study [2014] [OP0048]. *Ann Rheum Dis*, 2014, 73 (dopl. 2).
- Condon, M. B. – Ashby, D. – Proper, R. J., et al.: Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. *Ann Rheum Dis*, 2013, 72, s. 1280–1286.

Glukokortikoidy indukovaná osteoporóza, možnosti prevence a léčby

prof. MUDr. Jan Štěpán, DrSc. Revmatologický ústav a 1. LF UK, Praha

- Kanis, J. A. – Stevenson, M. – McCloskey, E. V. – Davis, S. – Lloyd-Jones, M.: Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. *Health Technol Assess*, 2007, 11, s. iii–v, ix–xi, 1–231.
- van Staa, T. P. – Leufkens, H. G. – Cooper, C.: The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. *Osteoporos Int*, 2002, 13, s. 777–787.
- Vosse, D. – de Vlam, K.: Osteoporosis in rheumatoid arthritis and ankylosing spondylitis. *Clin Exp Rheumatol*, 2009, 27, s. S62–S67.
- van Staa, T. P. – Abenhaim, L. – Cooper, C. – Zhang, B. – Leufkens, H. G.: Public health impact of adverse bone effects of oral corticosteroids. *Br J Clin Pharmacol*, 2001, 51, s. 601–607.
- van Staa, T. P. – Leufkens, H. G. – Abenhaim, L. – Zhang, B. – Cooper, C.: Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. *Rheumatology (Oxford)*, 2000, 39, s. 1383–1389.
- de Gregorio, L. H. – Lacativa, P. G. – Melazzi, A. C. – Russo, L. A.: Glucocorticoid-induced osteoporosis. *Arq Bras Endocrinol Metabol*, 2006, 50, s. 793–801.
- van Staa, T. P.: The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. *Calcif Tissue Int*, 2006, 79, s. 129–137.
- Angeli, A. – Guglielmi, G. – Dovio, A., et al.: High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. *Bone*, 2006, 39, s. 253–259.
- van Staa, T. P. – Leufkens, H. G. – Cooper, C.: Use of inhaled corticosteroids and risk of fractures. *J Bone Miner Res*, 2001, 16, s. 581–588.
- Gluck, O. S. – Murphy, W. A. – Hahn, T. J. – Hahn, B.: Bone loss in adults receiving alternate day glucocorticoid therapy. A comparison with daily therapy. *Arthritis Rheum*, 1981, 24, s. 892–898.
- De Vries, F. – Bracke, M. – Leufkens, H. G. – Lammers, J. W. – Cooper, C. – van Staa, T. P.: Fracture risk with intermittent high-dose oral glucocorticoid therapy. *Arthritis Rheum*, 2007, 56, s. 208–214.
- Silverman, S. – Curtis, J. – Saag, K., et al.: International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study. *Osteoporos Int*, 2015, 26, s. 419–420.
- Weinstein, R. S.: Clinical practice. Glucocorticoid-induced bone disease. *N Engl J Med*, 2011, 365, s. 62–70.
- Chappard, D. – Josselin, N. – Rouge-Maillart, C. – Legrand, E. – Basle, M. F. – Audran, M.: Bone microarchitecture in males with corticosteroid-induced osteoporosis. *Osteoporos Int*, 2007, 18, s. 487–494.
- Dalle Carbonare, L. – Bertoldo, F. – Valenti, M. T., et al.: Histomorphometric analysis of glucocorticoid-induced osteoporosis. *Micron*, 2005, 36, s. 645–652.
- Vedi, S. – Elkin, S. L. – Compston, J. E.: A histomorphometric study of cortical bone of the iliac crest in patients treated with glucocorticoids. *Calcif Tissue Int*, 2005, 77, s. 79–83.
- Mellibovsky, L. – Prieto-Alhambra, D. – Mellibovsky, F., et al.: Bone tissue properties measurement by reference point indentation in glucocorticoid-induced osteoporosis. *J Bone Miner Res*, duben 2015.
- Schakman, O. – Kalista, S. – Bertrand, L., et al.: Role of Akt/GSK3beta/beta-catenin transduction pathway in the muscle anti-atrophy action of insulin-like growth factor-1 in glucocorticoid-treated rats. *Endocrinology*, 2008, 149, s. 3900–3908.
- Patschan, D. – Loddenkemper, K. – Buttgerit, F.: Molecular mechanisms of glucocorticoid-induced osteoporosis. *Bone*, 2001, 29, s. 498–505.
- Oury, F. – Sumara, G. – Sumara, O., et al.: Endocrine regulation of male fertility by the skeleton. *Cell*, 2011, 144, s. 796–809.
- van Staa, T. P. – Laan, R. F. – Barton, I. P. – Cohen, S. – Reid, D. M. – Cooper, C.: Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. *Arthritis Rheum*, 2003, 48, s. 3224–3229.
- Dovio, A. – Perazzolo, L. – Osella, G., et al.: Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. *J Clin Endocrinol Metab*, 2004, 89, s. 4923–4928.
- Brábníková Marešová, K. – Pavelka, K. – Štěpán, J. J.: Acute effects of glucocorticoids on serum markers of osteoclasts, osteoblasts, and osteocytes. *Calcif Tissue Int*, 2013, 92, s. 354–361.
- Eastell, R. – Chen, P. – Saag, K. G., et al.: Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. *Bone*, 2010, 46, s. 929–934.
- Kanis, J. A. – Johansson, H. – Oden, A. – McCloskey, E. V.: Guidance for the adjustment of FRAX according to the dose of glucocorticoids. *Osteoporos Int*, 2011, 22, s. 809–816.
- van Staa, T. P. – Abenhaim, L. – Cooper, C. – Zhang, B. – Leufkens, H. G.: The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results. *Pharmacoepidemiol Drug Saf*, 2000, 9, s. 359–366.
- Szappanos, A. – Toke, J. – Lippai, D., et al.: Bone turnover in patients with endogenous Cushing's syndrome before and after successful treatment. *Osteoporos Int*, 2010, 21, s. 637–645.
- Lekamwasam, S. – Adachi, J. D. – Agnusdei, D., et al.: A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. *Osteoporos Int*, 2012, 23, s. 2257–2276.
- Richy, F. – Schacht, E. – Bruyere, O. – Ethgen, O. – Gourlay, M. – Reingster, J. Y.: Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis. *Calcif Tissue Int*, 2005, 76, s. 176–186.
- Lukert, B. P. – Johnson, B. E. – Robinson, R. G.: Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. *J Bone Miner Res*, 1992, 7, s. 1063–1069.
- Mok, C. C. – Ying, K. Y. – To, Ch., et al.: Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blind placebo-controlled trial. *Ann Rheum Dis*, 2011, 70, s. 778–784.
- Crawford, B. A. – Liu, P. Y. – Kean, M. T. – Bleasel, J. F. – Handelsman, D. J.: Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. *J Clin Endocrinol Metab*, 2003, 88, s. 3167–3176.
- Saag, K. G. – Shane, E. – Boonen, S., et al.: Teriparatide or alendronate in glucocorticoid-induced osteoporosis. *N Engl J Med*, 2007, 357, s. 2028–2039.
- Gluer, C. C. – Marin, F. – Ringe, J. D., et al.: Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. *J Bone Miner Res*, 2013, 28, s. 1355–1368.
- Fahleitner-Pammer, A. – Langdahl, B. L. – Marin, F., et al.: Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS). *Osteoporos Int*, 2011, 22, s. 2709–2719.
- Saag, K. G. – Emkey, R. – Schnitzer, T. J., et al.: Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. *N Engl J Med*, 1998, 339, s. 292–299.
- Reid, D. M. – Hughes, R. A. – Laan, R. F., et al.: Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. *J Bone Miner Res*, 2000, 15, s. 1006–1013.
- Wallach, S. – Cohen, S. – Reid, D. M., et al.: Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. *Calcif Tissue Int*, 2000, 67, s. 277–285.
- Dore, R. K. – Cohen, S. B. – Lane, N. E., et al.: Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. *Ann Rheum Dis*, 2010, 69, s. 872–875.
- Mok, C. C. – Ho, L. Y. – Ma, K. M.: Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: A 12-month randomized controlled trial. *Bone*, 2015, v tisku.
- Reid, D. M. – Devogelaer, J. P. – Saag, K., et al.: Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. *Lancet*, 2009, 373, s. 1253–1263.
- Majumdar, S. R. – Lix, L. M. – Morin, S. N. – Yogendran, M. – Metzge, C. J. – Leslie, W. D.: The disconnect between better quality of glucocorticoid-induced osteoporosis preventive care and better outcomes: a population-based cohort study. *J Rheumatol*, 2013, 40, s. 1736–1741.
- Overman, R. A. – Gourlay, M. L. – Deal, C. L. – Farley, J. F. – Brookhart, M. A. – Layton, J. B.: Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis. *Osteoporos Int*, 2015, v tisku.
- Thomas, T. – Horlait, S. – Ringe, J. D., et al.: Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice. *Osteoporos Int*, 2013, 24, s. 263–269.
- Giusti, A. – Hamdy, N. A. – Papapoulos, S. E.: Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies. *Bone*, 2010, 47, s. 169–180.
- Ma, Y. L. – Zeng, Q. Q. – Chiang, A. Y., et al.: Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment. *Bone*, 2014, 59, s. 139–147.

Glukokortikoidy v léčbě idiopatických zánětlivých myopatií

MUDr. Heřman Mann Revmatologický ústav a Klinika revmatologie 1. LF UK, Praha

- Dalakas, M. C.: Inflammatory Muscle Diseases. *N Engl J Med*, 2015, 372, s. 1734–1747.
- Betteridge, Z. E. – Gunawardena, H. – McHugh, N. J.: Novel auto-antibodies and clinical phenotypes in adult and juvenile myositis. *Arthritis Res Ther*, 2011, 13, s. 209.
- Joffe, M. M. – Love, L. A. – Leff, R. L., et al.: Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. *Am J Med*, 1993, 94, s. 379–387.
- Clarke, A. E. – Bloch, D. A. – Medsger, T. A. Jr. – Oddis, C. V.: A longitudinal study of functional disability in a national cohort of patients with polymyositis/dermatomyositis. *Arthritis Rheum*, 1995, 38, s. 1218–1224.
- van de Vlekkert, J. – Hoogendijk, J. E. – de Haan, R. J., et al.: Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial. *Neuromuscul Disord*, 2010, 20, s. 382–389.
- Ruperto, N. – Pistorio, A. – Oliveira, S., et al.: A randomized trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine versus prednisone plus methotrexate. *Arthritis Rheum*, 2012, 64 (dopl. 10), s. 2473.
- Tomasová Studýnková, J. – Mann, H. – Jarošová, K., et al.: A prospective, randomized, open-label, assessor-blind, multicenter study of efficacy and safety of combined treatment of methotrexate + glucocorticoids versus glucocorticoids alone in patients with polymyositis and dermatomyositis (Prometheus trial). *Ann Rheum Dis*, 2014, 73 (dopl. 2), s. 171.
- Levine, T.: Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series. *Drug Des Devel Ther*, 2012, 6, s. 133–139.

Glukokortikoidy v intraartikulární léčbě u zánětlivých revmatických onemocnění

MUDr. Radka Svobodová Revmatologický ústav, Praha

- Habib, G. S., et al.: Systemic effects of intra-articular corticosteroids. *Clin Rheumatol*, 2009, 28, s. 749–756.
- Hollander, J. L. – Brown, E. M. – Jessar, R. A., et al.: Hydrocortisone and cortisone injected into arthritis joint: comparative effects and use of hydrocortisone as a local antiarthritis agent. *JAMA*, 1951, 147, s. 16329–16335.
- Schwarz, S.: Intra-articular administration of triamcinolone acetonide: a preliminary report. *NY State J Med*, 1960, 60, s. 3422–3425.
- Kendall, P. H.: Triamcinolone hexacetonide. A new corticosteroid for intra-articular therapy. *Ann Phys Med*, 1967, 9, s. 55–58.
- Norcross, B. M. – Winter, J. A.: Methylprednisolone acetate: a single preparation suitable for both intra-articular and systemic use. *NY State J Med*, 1961, 61, s. 552–561.
- Roberts, H. J.: Local injection of a preparation containing two beta-methasone esters in the treatment of noninfectious musculoskeletal disorders. *J Am Geriatr Soc*, 1965, 13, s. 275–291.
- Möllmann, H. W. – Armbruster, B. – Barth, J., et al.: Analysis of shape, grain size distribution and aggregation of crystals in glucocorticoid-depot preparations. Analyse von Form, Korngrößenverteilung und Aggregation der Kristalle in Glukokortikoid-Depotpräparaten. *Akt Rheumatol*, 1990, 15, s. 101–124.
- Hochhaus, G. – Möllmann, H. – Barth, J.: Glukokortikoid für den intraartikulären Einsatz: Pharmakodynamische Charakterisierung durch Rezeptorbindungsstudien. *Akt Rheumatol*, 1990, 15, s. 66–69.
- Rohdewald, P. – Möllmann, H. W. – Hochhaus, G.: Rezeptoraffinitäten handelsüblicher Glukokortikoid-Depotpräparate zum Glukokortikoid-Rezeptor der menschlichen Lunge. *Atemw-Lungenkrkh*, 1984, 10, s. 484–489.
- Armstrong, R. D. – English, J. – Gibsn, T., et al.: Serum methylprednisolone levels following intra-articular injection of methylprednisolone acetate. *Ann Rheum Dis*, 1981, 40, s. 571–574.
- Bertouch, J. V. – Sallustio, B. C. – Mefflin, B. J., et al.: A comparison of plasma methylprednisolone concentrations following intraarticular injection in patients with rheumatoid arthritis and osteoarthritis. *Aust N Z Med*, 1983, 13, s. 583–585.
- Weitof, T. – Ronnblom, L.: Glucocorticoid resorption and influence of the hypothalamic-pituitary-adrenal axis after intra-articular treatment of the knee in resting and mobile patients. *Ann Rheumatol Dis*, 2006, 65, s. 955–957.
- Derendorf, H. – Möllmann, H. – Gruner, A., et al.: Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration. *Clin Pharmacol Ther*, 1986, 39, s. 313–317.
- Younes, M. – Nefati, F. – Touzi, M., et al.: Systemic effects of epidural and intra-articular glucocorticoid injections in diabetic and non-diabetic patients. *Joint Bone Spine*, 2007, 74, s. 472–476.
- von Hatz, H.: Lokale intraartikuläre Diagnostik und Therapie – Synovia-Analyse und Injektionstechniken der Gelenke. Gebundene Ausgabe – August 2009.
- Alex, P. – Szodoray, P. – Artur, E., et al.: Influence of intra-articular corticosteroid administration on serum cytokines in rheumatoid arthritis. *Clin Rheum*, 2007, 26, s. 845–848.
- Makrygiannakis, D. – Revu, S. – Engstrom, M., et al.: Local administration of glucocorticoid decreases synovial citrullination in rheumatoid arthritis. *Arthritis Res Ther*, 2012, 14, s. R20.
- af Klint, E. – Grundtman, C. – Engstrom, M., et al.: Intra-articular glucocorticoid treatment reduces inflammation in synovial cell infiltrations more efficiently than in synovial blood vessels. *Arthritis Rheum*, 2005, 53, s. 3880–3889.
- Makrygiannakis, D. – af Klint, E. – Catrina, S. B., et al.: Intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis. *Arthritis Rheum*, 2006, 54, s. 1463–1472.
- Emkey, R. D. – Lindsay, R. – Lyssy, J., et al.: The systemic effect of intra-articular administration of corticosteroid on markers of bone formation and bone resorption in patients with rheumatoid arthritis. *Arthritis Rheum*, 1996, 39, s. 277–282.
- Pavelka, K. – Vencovský, J.: Doporučení České revmatologické společnosti pro léčbu revmatoidní artritidy. *Čes Revmatol*, 2010, 4, s. 182–191.
- Smolen, J. S. – Landewé, R. – Bredveld, F. C., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. *Ann Rheum Dis*, 2014, 73, s. 492–509.
- Konai, M. S. – Vilar Furtado, R. N. – Dos Santos, M. F., et al.: Mono-articular corticosteroid injection versus systemic administration in the treatment of rheumatoid arthritis patients: a randomized double-blind controlled study. *Clin Exp Rheumatol*, 2009, 27, s. 214–221.
- Furtado, R., et al.: Polyarticular corticosteroid injection versus systemic administration in treatment of rheumatoid arthritis patients: a randomized controlled study. *J Rheumatol*, 2005, 32, s. 1691–1698.
- Bird, H. A. – Ring, E. F. J. – Bacon, P. A.: Thermographic and clinical comparison of 3 intra-articular steroid preparation in rheumatoid arthritis. *Ann Rheum Dis*, 1979, 38, s. 36–39.
- Blyth, T. – Stirling, A. – Coote, J., et al.: Injection of the rheumatoid knee does intra-articular methotrexate or rifampicin add to the benefits of triamcinolone hexacetonide. *Br J Rheumatol*, 1998, 37, s. 770–772.
- Axelsen, M. B. – Eshed, I. – Horslev-Petersen, K., et al.: A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomized controlled trial. *Ann Rheum Dis*, 2014, 2014, s. 2014, doi: 10.1136/annrheumdis-2013-204537.
- Jensen, T. W. – Hansen, M. S. – Horslev-Petersen, K., et al.: Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial. *Ann Rheum Dis*, 2014, 73, s. 1123–1129, doi: 10.1136/annrheumdis-2012-203171, Epub 9. 5. 2013.
- Weitof, T. – Rönnelid, J. – Knight, A., et al.: Outcome predictors of intra-articular glucocorticoid treatment for knee synovitis in patients with rheumatoid arthritis – a prospective cohort study. *Arthritis Res Ther*, 2014, 16, s. R129.
- Zulian, F. – Martini, G. – Gobber, D., et al.: Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial. *Rheumatology*, 2004, 43, s. 1288–1291.
- Eberhard, B. A. – Sison, M. C. – Gottlieb, B. S., et al.: Comparison of the intraarticular effectiveness of triamcinolone hexacetonide and triamcinolone acetonide in treatment of juvenile rheumatoid arthritis. *J Rheumatol*, 2004, 31, s. 2507–2512.
- Zulian, F. – Martini, G. – Gobber, D., et al.: Comparison of intra-articular triamcinolone hexacetonide and triamcinolone acetonide in oligoarticular juvenile idiopathic arthritis. *Rheumatology (Oxford)*, 2003, 42, s. 1254–1259.
- Balogh, Z. – Ruzsonyi, E.: Triamcinolone hexacetonide versus betamethazone. A double-blind comparative study of the long-term effects of intra-articular steroids in patients with juvenile chronic arthritis. *Scand J Rheumatol*, 1988, 67, s. 80–82.
- Honkanen, V. E. A. – Rautonen, J. K. – Pelkonen, P. M.: Intra-articular glucocorticoids in early juvenile chronic arthritis. *Acta Paediatr*, 1993, 82, s. 1072–1074.
- Bloom, B. J. – Alario, A. J. – Miller, L. C.: Intra-articular corticosteroid therapy for juvenile idiopathic arthritis: report of an experimental cohort and literature review. *Rheumatol Int*, 2011, 31, s. 749–756.
- Lanni, S. – Bertamino, M. – Consolaro, A., et al.: Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis. *Rheumatology*, 2011, 50, s. 1627–1634.
- Stoll, M. L. – Good, J. – Sharp, T., et al.: Intra-articular corticosteroid injections to the temporomandibular joints are safe and appear to be effective therapy in children with juvenile idiopathic arthritis. *J Oral Maxillofac Surg*, 2012, 70, s. 1802–1807.
- Cahill, A. M. – Cho, S. S. – Baskin, K. M., et al.: Benefit of fluoroscopically guided intra-articular long-acting corticosteroid injection for subtalar arthritis in juvenile idiopathic arthritis. *Pediatr Radiol*, 2007, 37, s. 544–548.
- Sherry, D. J. – Stein, L. D. – Reed, A. M., et al.: Prevention of leg length discrepancy in young children with pauciarticular juvenile rheumatoid arthritis by treatment with intraarticular steroids. *Arthritis Rheum*, 1999, 42, s. 2330–2334.
- Ringold, S. – Weiss, P. F. – Beukelman, T., et al.: 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. *Arthritis Rheum*, 2013, 65, s. 2499–2512, doi: 10.1002/art.38092.
- Pavelka, K.: Doporučení České revmatologické společnosti pro léčbu ankylozující spondylitidy. *Čes Revmatol*, 2012, 20, s. 4–11.
- Braun, J. – Berg, R. – Baraliakos, X., et al.: 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Ann Rheum Dis*, 2011, 70, s. 896–904.
- Maugars, Y. – Mythus, C. – Vilon, P., et al.: Corticosteroid injection of the sacroiliac joint in patients with seronegative spondylarthropathy. *Arthritis Rheum*, 1992, 35, s. 564–568.
- Braun, J. – Bollow, M. – Seyrekbasan, F., et al.: Computed tomography guided corticosteroid injection of the sacroiliac joint in patient with spondylarthropathy with sacroiliitis: clinical outcome and follow-up by dynamic magnetic resonance imaging. *J Rheumatol*, 1996, 23, s. 659–664.
- Bollow, M. – Braun, J. – Taupitz, M., et al.: CT-guided intraarticular corticosteroid injection into the sacroiliac joints in patients with spondylarthropathy: indication and follow-up with contrast enhanced MRI. *J Comput Assist Tomogr*, 1996, 20, s. 512–521.
- Maugars, Y. – Mythus, C. – Berthelot, J.-M., et al.: Assessment of the efficacy of sacroiliac corticosteroid injections in spondylarthropathies: a double-blind study. *Br J Rheumatol*, 1996, 35, s. 767–770.
- Hanly, J. G. – Mitchell, M. – MacMillan, L., et al.: Efficacy of sacroiliac corticosteroid injections in patients with inflammatory spondylarthropathy: results of a 6 month controlled study. *J Rheumatol*, 2000, 27, s. 719–722.
- Stöfla, J. – Vencovský, J. – Pavelka, K.: Doporučené postupy České revmatologické společnosti pro léčbu psoriatické artritidy. *Čes Revmatol*, 2012, 20, s. 13–18.
- Gossec, L. – Smolen, J. S. – Gaujoux-Viala, C.: European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. *Ann Rheum Dis*, 2012, 71, s. 4–12.
- Raynaud, J. P. – Buckland-Wright, C. – Ward, R., et al.: Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. *Arthritis Rheum*, 2003, 48, s. 370–377.
- Gottlieb, N. L. – Penneys, N. S. – Brown, Jr. H. E.: Periarticular perilymphatic skin atrophy after intra-articular corticosteroid injections. *JAMA*, 1978, 240, s. 559–560.
- Hatrick, M. – Roberty, M.: Facial flushing after intra-articular injection of steroid. *BMJ*, 1987, 295, s. 1380.
- Job-Deslandre, C. – Menkes, C. J.: Complication of intra-articular injections of triamcinolone hexacetonide in chronic arthritis in children. *Clin Exp Rheumatol*, 1990, 8, s. 413–416.
- Sparing, M. – Malleson, P. – Wood, B., et al.: Radiographic follow-up of joints injected with triamcinolone hexacetonide for the management of childhood arthritis. *Arthritis Rheum*, 1990, 33, s. 821–826.
- Breit, W. – Frosch, M. – Meyer, U., et al.: A subgroup-specific evaluation of the efficacy of intra-articular triamcinolone hexacetonide in juvenile chronic arthritis. *J Rheumatol*, 2000, 27, s. 2696–2702.
- Laroche, M. – Arlet, J. – Mazieres, B.: Osteonecrosis of the femoral and humeral heads after intra-articular corticosteroid injections. *J Rheumatol*, 1990, 17, s. 549–551.
- Holland, C. – Jaeger, L. – Smentkowski, U., et al.: Septic and aseptic complications of corticosteroid injections. *Dtsch Arztebl Int*, 2012, 109, s. 425–430.
- Seror, P. – Pluvinage, P. – d'Andre, F. L., et al.: Frequency of sepsis after local corticosteroid injection (an inquiry on 116000 injections in rheumatological private practice in France). *Rheumatology*, 1999, 38, s. 1272–1274.
- Larson, L. G.: Anaphylactic shock after IA administration of triamcinolone acetonide in a 35-year-old female. *Scan J Rheumatol*, 1989, 18, s. 441–442.
- Karh, J. – Yang, W. H.: An anaphylactic reaction to intra-articular triamcinolone: a case report and review of the literature. *Ann Allergy Asthma Immunol*, 2003, 90, s. 254–258.
- Melby, J. C.: Systemic corticosteroid therapy: pharmacology and endocrinologic considerations. *Ann Intern Med*, 1974, 81, s. 505–512.
- Weitof, T. – Uddenfeldt, P.: Importance of synovial fluid aspiration when injecting intra-articular corticosteroids. *Ann Rheum Dis*, 2000, 59, s. 233–235.
- Denis, E. – Ruysen-Witrand, A. – Mouterde, G., et al.: Use of glucocorticoids in rheumatoid arthritis – Practical modalities of glucocorticoid therapy: Recommendations for clinical practise based on data from the literature and expert opinion. *Joint Bone Spine*, 2010, 77, s. 451–457.
- Hashkes, P. J. – Laxer, R. M.: Medical treatment of juvenile idiopathic arthritis. *JAMA*, 2005, 294, s. 1671–1684.
- Garg, N. – Perry, L. – Deodhar, A.: Intra-articular and soft tissue injections, a systematic review of relative efficacy of various corticosteroids. *Clin Rheumatol*, 2014, 33, s. 1695–1706.

Nežádoucí účinky glukokortikoidů u autoimunitních onemocnění

MUDr. Šárka Forejtová Revmatologický ústav, Praha

- Listing, J. – Kewok, J. – Manger, B., et al.: Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNF α inhibitors and rituximab. *Ann Rheum Dis*, 2015, 74, s. 415–421.
- Gensler, L. S.: Glucocorticoids: Complications to anticipate and prevent. *The Neurohospitalist*, 2012, 3, s. 92–97.
- Becker, D. M. – Chamberlain, B. – Swank, R., et al.: Relationship between corticosteroids exposure and plasma lipid levels in heart transplant recipients. *Am J Med*, 1988, 85, s. 632–638.
- MacGregor, A. J. – Dhilon, V. B. – Binder, A., et al.: Fasting lipids and antidiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. *Ann Rheum Dis*, 1992, 51, s. 151–155.
- Petri, M. – Spence, D. – Bone, L. R. – Hochberg, M. C.: Coronary artery disease risk factors in Johns Hopkins Lupus Cohort: prevalence, recognition by patients and preventive practices. *Medicine* (Baltimore), 1992, 71, s. 291–302.
- Manzi, S. – Meilahn, E. N. – Rairie, J. E., et al.: Age-specific incidence rates of myocardial infarction and angina in woman with systemic lupus erythematosus: comparison with Framingham Study. *Am J Epidemiol*, 1997, 145, s. 408–415.
- Petri, M. – Perez-Gutthann, S. – Spence, D., et al.: Risk factors for coronary artery disease in patients with systemic lupus erythematosus. *Am J Med*, 1992, 93, s. 513–519.
- Wallberg-Jonsson, S. – Johansson, H. – Ohman, M. L., et al.: Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective-cohort study from disease onset. *J Rheumatol*, 1999, 26, s. 2562–2571.
- Boers, M. – Nurmohamrd, M. T. – Doelman, C. J., et al.: Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. *Ann Rheum Dis*, 2003, 62, s. 842–845.
- Parker, B. – Bruce, I. N.: SLE and metabolic syndrome. *Lupus*, 2013, 22, s. 1259–1266.
- Albrecht, K. – Huscher, D. – Richter, J., et al.: Changes in referral, treatment and outcomes in patients with systemic lupus erythematosus in Germany in the 1990s and the 2000s. *Lupus Science&Medicine*, 2014, 1, s. 1–7.
- Wei, L. – MacDonald, T. M. – Walker, B. R.: Taking corticosteroids by prescription is associated with subsequent cardiovascular disease. *Ann Intern Med*, 2004, 141, s. 764–770.
- Mason, J. W. – O'Connell, J. B. – Heskowitz, A., et al.: A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. *N Engl J Med*, 1995, 333, s. 269–275.
- Whitworth, J. A. – Gordon, D. – Andrews, J., et al.: The hypertensive effect of synthetic glucocorticoids in man: role of sodium and volume. *J Hypertens*, 1989, 7, s. 537–549.
- Jackson, S. H. – Beevers, D. G. – Myers, K.: Does long term low-dose corticosteroid therapy cause hypertension? *Clin Sci (Land)*, 1981, 61 (dopl.), s. 391–393.
- van Tuyt, L. H. – Lems, W. F. – Voskuyl, A. E., et al.: Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial. *Ann Rheum Dis*, 2008, 6, s. 1574–1577.
- Mazzantini, M. – Torre, C. – Miccoli, M., et al.: Adverse events during long term low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study. *J Rheumatol*, 2012, 39, s. 552–557.
- Da Silva, J. A. P. – Jacobs, J. W. G. – Kirwan, J. R., et al.: Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. *Ann Rheum Dis*, 2006, 65, s. 285–293.
- McHugh, M. I. – Tanboga, G. – Wilkinson, R.: Alternate day steroids and blood pressure control after renal transplantation. *Proc Eur Dial Transplant Assoc*, 1980, 17, s. 496–501.
- Eastel, R.: Management of corticosteroid-induced osteoporosis. *J Intern Med*, 1995, 237, s. 439–447.
- Ladder, M. C. – Lems, W. F. – Kostence, P. J., et al.: Bone loss due to glucocorticoids: update of systemic review of prospective studies in rheumatoid arthritis and other diseases. *Ann Rheum Dis*, 2003, 62 (dopl.), s. 94.
- van Staa, T. P. – Leufkens, H. G. – Abenheim, L., et al.: Use of oral corticosteroids and risk of fracture. *J Bone Miner Res*, 2000, 15, s. 993–1000.
- Ninomiya, S.: An epidemiological survey of idiopathic avascular necrosis of the femoral head in Japan. *Annual Report of Japanese Investigation Committee for Intractable Disease*. Osaka, University Publisher, 1984.
- Zonana-Nacah, A. – Barr, S. G. – Magder, L. S., et al.: Damage in systemic lupus erythematosus and its association with corticosteroids. *Arthritis Rheum*, 2000, 43, s. 1801–1808.
- Vreden, S. G. – Hermus, A. R. – van Liessum, P. A., et al.: Aseptic bone necrosis in patients on glucocorticoid replacement therapy. *Neth J Med*, 1991, 39, s. 153–157.
- Minetto, M. A. – Lanfranco, F. – Motta, G., et al.: Steroid myopathy: some unresolved issues. *J Endocrinol Invest*, 2011, 34, s. 370–375.
- Barnes, B. J. – Adcock, I. M.: Glucocorticoid resistance in inflammatory diseases. *Lancet*, 2009, 373, s. 1905–1917.
- Gurwitz, J. H. – Bohn, R. L. – Glynn, R. J., et al.: Glucocorticoids and the risk of initiation of hypoglycemic therapy. *Arch Intern Med*, 1994, 154, s. 97–101.
- Kavanaugh, A. – Wells, A. F.: Benefits and risk of low-dose glucocorticoid treatment in the patient with rheumatoid arthritis. *Rheumatology*, 2014, 53, s. 1742–1751.
- van Everdingen, A. A. – Jacobs, J. W. – Reesema, D. R. – Bijlsma, J. W.: Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. *Ann Intern Med*, 2002, 136, s. 1–12.
- Nanesen, N. M. – Genta, M. S.: The effects of immunosuppressive and antiinflammatory medications on fertility, pregnancy and lactation. *Ann Intern Med*, 2000, 160, s. 610–619.
- Covar, R. A. – Lejny, D. Y. – McCormick, D., et al.: Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma. *J Allergy Clin Immunol*, 2000, 106, s. 651–659.
- Pedrosa, M. C. – Rohrer, R. M. – Kaplan, M. M.: Alternate-day prednisone in the maintenance immunosuppressive therapy after orthotopic liver transplantation. *Clin Transplant*, 1995, 9, s. 322–325.
- Saag, K. G. – Koehnke, R. – Caldwell, J. R., et al.: Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. *Am J Med*, 1994, 96, s. 115–123.
- Ruiz-Arzuza, I. – Ugarte, A. – Cabezas-Rodriguez, I., et al.: Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. *Rheumatology*, 2014, 53, s. 1470–1476.
- Tripathi, R. C. – Parapuram, S. K. – Tripathi, B. J., et al.: Corticosteroids and glaucoma risk. *Drug Aging*, 1999, 15, s. 439–450.
- Daniel, B. S. – Orchard, D.: Ocular side-effects of topical corticosteroids: what a dermatologist needs to know. *Australas J Dermatol*, 5, 3, 2015, publikováno online.
- Hoes, J. N. – Jacobs, J. W. – Boers, M., et al.: EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. *Ann Rheum Dis*, 2007, 66, s. 1560–1567.
- Bonn, H. O. – Blitzer, B. L.: No association of adrenocorticosteroid therapy and peptic ulcer. *N Engl J Med*, 1976, 294, s. 473–479.
- Messer, J. – Reitman, D. – Sacks, H. S., et al.: Association of adrenocorticosteroid therapy and peptic ulcer disease. *N Engl J Med*, 1983, 309, s. 21–24.
- Piper, J. M. – Ray, W. A. – Daugherty, J. R. – Griffin, M. R.: Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. *Ann Intern Med*, 1991, 114, s. 735–740.
- Bonn, H. O. – Poynard, T.: Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. *J Intern Med*, 1994, 236, s. 619–632.
- Garcia Rodriguez, L. A. – Hernández-Díaz, S.: The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combination of these agents. *Arthritis Res*, 2001, 3, s. 97–101.
- Luo, J. C. – Chang, F. Y. – Lin, H. Y., et al.: The potential risk factors leading to peptic ulcer formation in autoimmune disease patients receiving corticosteroid treatment. *Aliment Pharmacol Ther*, 2002, 16, s. 1241–1248.
- Wu, C. Y. – Poon, S. K. – Chen, G. H., et al.: Interaction between *Helicobacter pylori* and non-steroidal antiinflammatory drugs in peptic ulcer bleeding. *Scan J Gastroenterol*, 1999, 34, s. 234–237.
- Stuck, A. E. – Minder, C. E. – Frey, F. J.: Risk of infectious complications in patients taking glucocorticosteroids. *Rev Infect Dis*, 1989, 11, s. 954–963.
- Coluccia, D. – Wolf, O. T. – Kollias, S., et al.: Glucocorticoid therapy-induced memory deficits: acute versus chronic effects. *J Neurosci*, 2008, 28, s. 3474–3478.
- Bhangle, S. D. – Kamer, N. – Rosenstein, E. D.: Corticoid-induced neuropsychiatric disorders: review and contrast with neuropsychiatric lupus. *Rheumatol Int*, 2013, 33, s. 1923–1932.
- Lewis, D. A. – Smith, R. E.: Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature. *J Affect Disord*, 1983, 5, s. 319–332.
- Reckart, M. D. – Eisendrath, S. J.: Exogenous corticosteroid effect on mood and cognition: case presentations. *Int J Psychosom*, 1990, 37, s. 57–61.
- Gourley, M. F. – Austin, H. A. – Scott, D., et al.: Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. *Ann Intern Med*, 1996, 125, s. 549–557.
- van der Goes, M. C. – Jacobs, J. W. B. – Boers, M., et al.: Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendation for clinical trials and daily practice. *Ann Rheum Dis*, 2010, 69, s. 1913–1919.

Golimumab v kombinované léčbě aktivní revmatoidní artritidy v širší klinické praxi

prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha

- Domne, B. – Dasgupta, B. – Louw, I., et al.: Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study. *Ann Rheum Dis*, 2014, 73, s. 1477–1486.
- Keystone, E. C. – Genovese, M. C. – Klareskog, L., et al.: Golimumab, a human antibody to tumour necrosis factor (alpha) given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. *Ann Rheum Dis*, 2009, 68, s. 789–796.
- Emery, P. – Fleischmann, R. M. – Moreland, L. W., et al.: Golimumab, a human antitumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomised, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. *Arthritis Rheum*, 2009, 60, s. 2272–2283.
- Smolen, J. S. – Kay, J. – Doyle, M. K., et al.: Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study) a multicentre, randomised, double blind, placebo controlled phase III. trial. *Lancet*, 2009, 374, s. 210–221.
- Pavelka, K. – Szekanez, Z. – Damjanov, N., et al.: Induction of response with etanercept – methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study. *Clin Rheumatol*, 2013, 32, s. 1275–1281.
- Pavelka, K. – Vencovsky, J.: Doporučení České revmatologické společnosti pro léčbu revmatoidní artritidy. *Čes Revmatol*, 2010, 4, s. 182–191.
- Combe, B., et al.: 2013 as 10.1136/annrheumdis-2013-203229.

Výsledky léčby abataceptem hodnocené dle ACR-EULAR kritérií

prof. Ing. Jaroslav Petr, DrSc. Praha

- 1 Smolen, J. S. – Wollenhaupt, J. – Gomez-Reino, J. J., et al.: Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE). *Arthritis Research & Therapy*, 2015, 17, s. 157.
- 2 Westhovens, R. – Robles, M. – Ximenes, A. C., et al.: Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. *Annals of the Rheumatic Diseases*, 2009, 68, s. 1870–1877.

Komentář k článku:

Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept—treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE).

prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha

- 1 Smolen, J. S. – Aletaha, D. – Bijlsma, J. W., et al.: Treating rheumatoid arthritis to target: recommendations of an international task force. *Ann Rheum Dis*, 2010, 69, s. 631–637.
- 2 Smolen, J. S. – Breedveld, C. F. – Burmester, G. R., et al.: Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. *Ann Rheum Dis*, 2015, 0, s. 1–13, doi: 10.1136/annrheumdis-2015-207524.
- 3 Smolen, J. S. – Breedveld, F. C. – Schiff, M. H., et al.: A simplified disease activity index for rheumatoid arthritis for use in clinical practice. *Rheumatology*, 2003, 42, s. 244–257.
- 4 Westhovens, R. – Robles, M. – Ximenes, A. C., et al.: Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. *Ann Rheum Dis*, 2009, 68, s. 1870–1877.
- 5 Smolen, J. S. – Wollenhaupt, J. – Gomez-Reino, J. J., et al.: Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept—treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE). *Arthritis Res Ther*, 2015, 17, s. 157, doi: 10.1186/s13075-015-0671-9.
- 6 Emery, P. – Burmester, G. R. – Bykerk, V. P., et al.: Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. *Ann Rheum Dis*, 2015, 74, s. 19–26.
- 7 Huizinga, T. W. G. – Emery, P. – Westhovens, R., et al.: Rate of anti-cyclic citrullinated peptide antibody and rheumatoid factor seroconversion in patients with undifferentiated arthritis or early rheumatoid arthritis treated with abatacept. *Arthritis Rheum*, 2011, 63, s. S872.

Febuxostat šetří funkci ledvin u dny

MUDr. Lenka Petrů | MUDr. Jakub Závada Ph.D. Revmatologický ústav, Praha

- 1 Annemans, L. – Spaepen, E. – Gaskin, M., et al.: Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. *Ann Rheum Dis*, 2008, 67, s. 960–966.
- 2 See, L. C. – Kuo, C. F. – Chuang, F. H., et al.: Serum uric acid is independently associated with metabolic syndrome in subjects with and without a low estimated glomerular filtration rate. *J Rheumatol*, 2009, 36, s. 1691–1698.
- 3 Shankar, A. – Klein, R. – Klein, B. E., et al.: The association between serum uric acid level and long-term incidence of hypertension: Population-based cohort study. *J Hum Hypertens*, 2006, 20, s. 937–945.
- 4 Zhang, W. – Doherty, M. – Bardin, T., et al.: EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESICST). *Ann Rheum Dis*, 2006, 65, s. 1312–1324.
- 5 Jordan, K. M. – Cameron, J. S. – Snaith, M., et al.: British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. *Rheumatology (Oxford)*, 2007, 46, s. 1372–1374.
- 6 Goicoechea, M. – de Vinuesa, S. – Verdalles, U., et al.: Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. *Clin J Am Soc Nephrol*, 2010, 5, s. 1388–1393.
- 7 Stamp, L. K. – Taylor, W. J. – Jones, P. B., et al.: Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. *Arthritis Rheum*, 2012, 64, s. 2529–2536.
- 8 Takano, Y. – Hase-Aoki, K. – Horiuchi, H., et al.: Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. *Life Sci*, 2005, 76, s. 1835–1847.
- 9 Khosravan, R. – Grabowski, B. A. – Wu, J. T., et al.: Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects. *Br J Clin Pharmacol*, 2008, 65, s. 355–363.
- 10 Khosravan, R. – Grabowski, B. A. – Mayer, M. D., et al.: The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. *J Clin Pharmacol*, 2006, 46, s. 88–102.
- 11 Mayer, M. D. – Khosravan, R. – Vernillet, L., et al.: Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. *Am J Ther*, 2005, 12, s. 22–34.
- 12 Edwards, N. L.: Febuxostat: a new treatment for hyperuricaemia in gout. *Rheumatology (Oxford)*, 2009, 48 (dopl. 2), s. ii15–ii9.
- 13 Kuo, C. F. – Luo, S. F. – See, L. C., et al.: Hyperuricaemia and accelerated reduction in renal function. *Scand J Rheumatol*, 2011, 40, s. 116–121.
- 14 Kanbay, M. – Solak, Y. – Dogan, E., et al.: Uric acid in hypertension and renal disease: the chicken or the egg? *Blood Purif*, 2010, 30, s. 288–295.
- 15 The Kidneys in Gout. *British Medical Journal*, 1963, 1, s. 700.
- 16 Barlow, K. A. – Beilin, L. J.: *Renal disease in primary gout*. 1968.
- 17 Berger, L.: Impaired renal function in gout: Its association with hypertensive vascular disease and intrinsic renal disease. *Am J Med*, 1982, 72, s. 95–100.
- 18 Kang, D. H. – Nakagawa, T. – Feng, L., et al.: A role for uric acid in the progression of renal disease. *J Am Soc Nephrol*, 2002, 13, s. 2888–2897.
- 19 Sanchez-Lozada, L. G. – Tapia, E. – Santamaria, J., et al.: Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. *Kidney Int*, 2005, 67, s. 237–247.
- 20 Sanchez-Lozada, L. G. – Soto, V. – Tapia, E., et al.: Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. *Am J Physiol Renal Physiol*, 2008, 295, s. F1134–F1141.
- 21 Sanchez-Lozada, L. G. – Lanaspa, M. A. – Cristobal-Garcia, M., et al.: Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations. *Nephron Exp Nephrol*, 2012, 121, s. e71–e78.
- 22 Johnson, R. J. – Kang, D. H. – Feig, D., et al.: Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? *Hypertension*, 2003, 41, s. 1183–1190.
- 23 Nakagawa, T. – Mazzali, M. – Kang, D. H., et al.: Uric acid—a uremic toxin? *Blood Purif*, 2006, 24, s. 67–70.
- 24 Wang, H. – Wei, Y. – Kong, X., et al.: Effects of urate-lowering therapy in hyperuricemia on slowing the progression of renal function: a meta-analysis. *J Ren Nutr*, 2013, 23, s. 389–396.
- 25 Ito, S. – Naritomi, H. – Ojihara, T., et al.: Impact of serum uric acid on renal function and cardiovascular events in hypertensive patients treated with losartan. *Hypertens Res*, 2012, 35, s. 867–873.
- 26 Schumacher, H. R. Jr. – Becker, M. A. – Wortmann, R. L., et al.: Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. *Arthritis Rheum*, 2008, 59, s. 1540–1548.
- 27 Becker, M. A. – Schumacher, H. R. – Espinoza, L. R., et al.: The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. *Arthritis Res Ther*, 2010, 12, s. R63.
- 28 Sezai, A. – Soma, M. – Nakata, K. I., et al.: Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD). *J Cardiol*, 2015.
- 29 Omori, H. – Kawada, N. – Inoue, K., et al.: Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy. *Clin Exp Nephrol*, 2012, 16, s. 549–556.
- 30 Tsuda, H. – Kawada, N. – Kaimori, J. Y., et al.: Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress. *Biochem Biophys Res Commun*, 2012, 427, s. 266–272.
- 31 Rajendra, N. S. – Ireland, S. – George, J., et al.: Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. *J Am Coll Cardiol*, 2011, 58, s. 820–828.
- 32 George, J. – Carr, E. – Davies, J., et al.: High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. *Circulation*, 2006, 114, s. 2508–2516.
- 33 Johnson, R. J. – Nakagawa, T. – Jalal, D., et al.: Uric acid and chronic kidney disease: which is chasing which? *Nephrol Dial Transplant*, 2013, 28, s. 2221–2228.

Co je cílem léčby revmatoidní artritidy?

MUDr. Heřman Mann Revmatologický ústav a Klinika revmatologie 1. LF UK, Praha

- 1 **Cutolo, M. – Kotas, G. D. – van Riel, P. L.:** Burden of disease in treated rheumatoid arthritis patients: going beyond the joint. *Semin Arthritis Rheum*, 2014, 43, s. 479–488.
- 2 **Carr, A. – Hewlett, S. – Hughes, R. – Mitchell, H., et al.:** Rheumatology outcomes: the patient's perspective. *J Rheumatol*, 2003, 30, s. 880–883.
- 3 **Anderson, J. K. – Zimmermann, L. – Caplan, L. – Michaud, K.:** Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5), Chronic Arthritis Systemic Index (CASII), Patient-Based Disease Activity Score With ESR (PDAS1) and Patient-Based Disease Activity Score without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI-RA). *Arthritis Care Res (Hoboken)*, 2011, 63, s. 514–536.
- 4 **Nelson, D. T. – Smolen, J. S. – Wells, G., et al.:** American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. *Arthritis Rheum*, 2011, 63, s. 573–586.
- 5 **Šléglová, O. – Dušek, L. – Olejárová, M., et al.:** Posuzování funkční schopnosti u pacientů s revmatoidní artritidou; validace české verze Stanfordského dotazníku Health Assessment Questionnaire (HAQ). *Čes Revmatol*, 2010, 18, s. 73–83.
- 6 **Smolen, J. S. – Breedveld, F. C. – Burmester, G. R., et al.:** Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. *Ann Rheum Dis*, nejprve publikováno online 12. 5. 2015, doi: 10.1136/annrheumdis, 2015, s. 207–524.
- 7 **Smolen, J. S. – Landewé, R. – Breedveld, F. C., et al.:** EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. *Ann Rheum Dis*, 2014, 73, s. 492–509.
- 8 **Emery, P. – Kavanaugh, A. – Bao, Y., et al.:** Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis? *Ann Rheum Dis*, nejprve publikováno online 19. 8. 2014, doi: 10.1136/annrheumdis, 2014, s. 205–302.

Význam subkutánního metotrexátu v léčbě revmatických onemocnění

doc. MUDr. Radim Bečvář, CSc. Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha

- 1 **Svobodová, R.:** Současné postavení metotrexátu v terapii revmatických chorob. *Farmakoterapie*, 2006, s. 671–674.
- 2 **Visser, K. – van der Heijde, D.:** Optimal dosage and route of administration of methotrexate in rheumatoid arthritis. A systematic review of literature. *Ann Rheum Dis*, 2009, 68, s. 1094–1099.
- 3 **Bannwarth, B. – Pehourcq, F. – Schaefer-Baekke, T. – Dehais, J.:** Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. *Clin Pharmacokin*, 1996, 30, s. 194–210.
- 4 **Matherly, L. H. – Goldman, D. I.:** Membrane transport of folates. *Vitamin Horm*, 2003, 66, s. 403–456.
- 5 **Tuková, J. – Chládek, J. – Němcová, D. – Chládková, J. – Doležalová, P.:** Methotrexate bioavailability after oral and subcutaneous administration in children with juvenile idiopathic arthritis. *Clin Exp Rheumatol*, 2009, 27, s. 1047–1053.
- 6 **Albrecht, K. – Mueller-Ladner, U.:** Side effects and management of side effects of methotrexate in rheumatoid arthritis. *Clin Exp Rheumatol*, 2010, 28, s. 95–101.
- 7 **Becker, M. L. – Van Haandel, L. – Gaedick, R., et al.:** Analysis of methotrexate polyglutamates in patients with juvenile idiopathic arthritis: effect of route of administration on variability of intracellular methotrexate polyglutamate concentrations. *Arthritis Rheum*, 2010, 62, s. 1803–1812.
- 8 **Dalrymple, J. – Stamp, L. – O'Donnel, J., et al.:** Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. *Arthritis Rheum*, 2008, 58, s. 3299–3308.
- 9 **Stamp, L. K. – O'Donnel, J. – Chapman, P. T., et al.:** Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy. *Arthritis Rheum*, 2010, s. 62339–62368.
- 10 **Fiehn, C. – Mueller-Ladner, U. – Gay, S., et al.:** Albumin-coupled methotrexate (MTX-HSA) is a new anti-arthritis drug which acts synergistically to MTX. *Rheumatology (Oxford)*, 2004, 43, s. 1097–1105.
- 11 **Neumann, E. – Frei, E. – Funk, D., et al.:** Native albumin for targeted drug delivery. *Expert Opin Drug Deliv*, 2010, 7, s. 915–925.
- 12 **Rozin, A. – Schapira, D. – Baldir-Gurman, A., et al.:** Relapse of rheumatoid arthritis after substitution of oral for parenteral administration of methotrexate. *Ann Rheum Dis*, 2002, 61, s. 756–757.
- 13 **Hoekstram, M. – Haagsma, C. – Nerv, C., et al.:** Splitting high-dose oral methotrexate improves bioavailability: a Pharmacokinetic study in patients with rheumatoid arthritis. *J Rheumatol*, 2006, 33, s. 481–485.
- 14 **Braun, J. – Kästner, P. – Flaxenberg, P., a MC-MTX.6/RH Study Group.:** Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. *Arthritis Rheum*, 2008, 58, s. 73–81.
- 15 **Scott, D. G. – Claydon, P. – Ellis, C.:** Retrospective evaluation of continuation rates following a switch to subcutaneous methotrexate in rheumatoid arthritis patients failing to respond to or tolerate oral methotrexate: the MENTOR study. *Scand J Rheumatol*, 2014, 43, s. 470–476.
- 16 **Demary, W. – Schwenke, H. – Rockwitz, K., et al.:** Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experience. *Patient Preference and Adherence*, 2014, 8, s. 1061–1071.

Postavení kanakinumabu v léčbě akutní dny

MUDr. Jakub Závada, Ph.D. Revmatologický ústav, Praha

- 1 **Annemans, L. – Spaepen, E. – Gaskin, M., et al.:** Prevalence, comorbidities and management in general practice 2000–2005. *Ann Rheum Dis*, 2008, 67, s. 960–966, Epub 2. 11. 2007.
- 2 **Zhu, Y. – Pandya, B. J. – Choi, H. K.:** Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. *Arthritis Rheum*, 2011, 63, s. 3136–3141.
- 3 **Roddy, E. – Roberty, M.:** Epidemiology of gout. *Arthritis Res Ther*, 2010, 12, s. 223.
- 4 **Zhu, Y. – Pandya, B. J. – Choi, H. K.:** Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. *Am J Med*, 2012, 125, s. 679–687.
- 5 **Martinon, F. – Pettrilli, V. – Mayor, A., et al.:** Gout-associated uric acid crystals activate the NALP3 inflammasome. 2006, *Nature*, 440, s. 237–241.
- 6 **Crittenden, D. B. – Pillinger, M. H.:** New therapies for gout. *Annu Rev Med*, 2013, 64, s. 325–337.
- 7 **So, A. – De Smedt, T. – Revaz, S., et al.:** A pilot study of IL-1 inhibition by anakinra in acute gout. *Arthritis Res Ther*, 2007, 9, s. R28.
- 8 **Terkeltaub, R. A. – Schumacher, H. R. – Carter, J. D., et al.:** Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. *Arthritis Res Ther*, 2013, 15, s. R25.
- 9 **Schumacher, H. R. – Sundry, J. S. – Terkeltaub, R., et al.:** Rilonacept (IL-1 Trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase 2 clinical trial. *Arthritis Rheum*, 2012, 64, s. 876–884.
- 10 **Schlesinger, N.:** Kanakinumab in gout. *Expert Opin Biol Ther*, 2012, 12, s. 1265–1275.
- 11 **Schlesinger, N. – Lin Liao, H. Y. – De Meulemeester, M., et al.:** Kanakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol therapy: results of a double-blind, randomized study. *Ann Rheum Dis*, 2011, 70, s. 1264–1271.
- 12 **Schlesinger, N. – Alten, R. E. – Bardin, T., et al.:** Kanakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. *Ann Rheum Dis*, 2012, 71, s. 1839–1848.
- 13 **Richette, P. – Garay, R.:** Novel drug discovery strategies for gout. *Expert Opin Drug Discov*, 2013, 8, s. 183–189.
- 14 **Fels, E. – Sundry, J. S.:** Refractory gout: what is it and what to do about it? *Curr Opin Rheumatol*, 2008, 20, s. 198–202.
- 15 **Keenan, R. T. – O'Brien, W. R. – Lee, K. H., et al.:** Prevalence of contraindications and prescription of pharmacologic therapies for gout. *Am J Med*, 2011, 124, s. 155–163.

Vliv tocilizumabu na příznaky deprese u nemocných s revmatoidní artritidou

MUDr. Heřman Mann Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha

- 1 Belmaker, R. H. – Major, A. G.: Depressive disorder. *N Engl J Med*, 2008, 358, s. 55–68.
- 2 Capuron, L. – Miller, A. H.: Immune system to brain signaling: neuropsychopharmacological implications. *Pharmacol Ther*, 2011, 130, s. 226–238.
- 3 Müller, N. – Schwarz, M. J., et al.: The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. *Mol Psychiatry*, 2006, 11, s. 680–684.
- 4 Matcham, F. – Rayner, L., et al.: The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. *Rheumatology* (Oxford), 2013, 52, s. 2136–2148.
- 5 Bruce, T. O.: Comorbid depression in rheumatoid arthritis: pathophysiology and clinical implications. *Curr Psychiatry Rep*, 2008, 10, s. 258–264.
- 6 Ang, D. C. – Choi, H., et al.: Comorbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis. *J Rheumatol*, 2005, 32, s. 1013–1019.
- 7 Townes, S. V. – Furst, D. E. – Thenkondar, A.: The impact of tocilizumab on physical function and quality of life in patients with rheumatoid arthritis: a systematic literature review and interpretation. *Open Access Rheumatology: Research and Reviews*, 2012, 4, s. 87–92.
- 8 Traki, L. – Rostom, S., et al.: Responsiveness of the EuroQol EQ-5D and Hospital Anxiety and Depression Scale (HADS) in rheumatoid arthritis patients receiving tocilizumab. *Clin Rheumatol*, 2014, 33, s. 1055–1060.

Imunogenicita inhibitorů TNF α – zaměřeno na etanercept

MUDr. Hana Ciferská, Ph.D. | MUDr. Monika Urbanová | MUDr. Liliana Šedová
Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha

- 1 Lyu, R. – Govoni, M. – Ding, Q., et al.: Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany. *Rheumatol Int*, 28. 8. 2015, Epub před tiskem.
- 2 Chen, Y. F1. – Jobanputra, P. – Barton, P., et al.: A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. *Health Technol Assess*, 2006, 10, s. 1–229.
- 3 Thomas, S. S. – Borazan, N. – Barroso, N., et al.: Comparative immunogenicity of TNF inhibitors: Impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis. *BioDrugs*, 18. 8. 2015, Epub před tiskem.
- 4 van Schouwenburg, P. A. – Rispen, T. – Wolbink, G. J.: Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. *Nature Reviews Rheumatology*, 2013, 9, s. 164–172.
- 5 Braun, J. – Kalden, J. R.: Biologics in the treatment of rheumatoid arthritis and ankylosing spondylitis. *Clin Exp Rheumatol*, 2009, 27, dopl. S164–S167.
- 6 Mazilu, D. – Opis, D. – Gainaru, C., et al.: Monitoring drug and anti-drug levels: a rational approach in rheumatoid arthritis patients treated with biologic agents who experience in adequate response while being on a stable biologic treatment. *BioMed Research International*, 2014, Article ID 702701, 2014, s. 8.
- 7 Hostino, M. – Yoshio, T. – Onishi, S., et al.: Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritis. *Mod Rheumatol*, 2012, 22, s. 532–540.
- 8 Jani, M. – Barton, A. – Warren, R. B., et al.: The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. *Rheumatology* (Oxford), 2014, 53, s. 213–222.
- 9 de Vries, M. K. – Wolbink, G. J. – Stapel, S. O., et al.: An efficacy of infliximab in ankylosing spondylitis is correlated with antibody formation. *Ann Rheum Dis*, 2007, 66, s. 133–134.
- 10 de Vries, M. K. – van der Horst-Bruinsma, I. E. – Nurmohamed, M. T., et al.: Immunogenicity does not influence treatment with etanercept in Patients with ankylosing spondylitis. *Ann Rheum Dis*, 2009, 68, s. 531–535.
- 11 Klareskog, L. – Gaubitz, M. – Rodriguez-Valverde, V., et al.: Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. *Clin Exp Rheumatol*, 2011, 29, s. 238–247.
- 12 Emery, P. – Vencovský, P. – Sylwestrzak, A., et al.: A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. *Ann Rheum Dis*, doi:10.1136/annrheumdis-2015, s. 207–588.
- 13 Schellekens, H.: Relationship between biopharmaceutical immunogenicity of epoetin alfa and pure red cell aplasia. *Curr Med Res Opin*, 2003, 19, s. 433–434.
- 14 Gribben, J. G. – Devereux, S. – Thomas, N. S., et al.: Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. *Lancet*, 1990, 335, s. 434–437.
- 15 Felipe, V. – Hawe, A. – Schellekens, H. – Jiskoot, W.: Aggregation and immunogenicity of therapeutic proteins. In: Wang, W. – Roberts, C. (eds): *Aggregation of Therapeutic Proteins*. John Wiley and Sons, NJ, USA, 2010.
- 16 European Medicines Agency: *Enbrel (etanercept) EU Summary of Product Characteristics*. Dostupné z: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_Product_Information/human/000262/WC500027361.pdf, vyhledáno 18. 8. 2015.
- 17 Baumgartner, S. W. – Fleischmann, R. M. – Moreland, L. W., et al.: Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability. *J Rheumatol*, 2004, 31, s. 1532–1537.
- 18 Davis, J. C. – van der Heijde, D. M. – Braun, J., et al.: Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96-weeks. *Ann Rheum Dis*, 2005, 64, s. 1557–1562.
- 19 van der Heijde, D. – Landewe, R. – Ory, P., et al.: Two-year etanercept therapy does not inhibit radiographic progression in patients with ankylosing spondylitis. *Ann Rheum Dis*, 2006, 65, dopl. II, s. 81.
- 20 van der Heijde, D. – Landewé, R. – Einstein, S., et al.: Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. *Arthritis Rheum*, 2008, 58, s. 1324–1331.
- 21 Gottlieb, A. B. – Kirck, L. – Eisen, D., et al.: Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study. *J Dermatolog Treat*, 2006, 17, s. 343–352.
- 22 Sterry, W. – Ortonne, J. P. – Kirkham, B., et al.: Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. *BMJ*, 2010, 2, 340, s. c147.
- 23 Gladman, D. D. – Bombardier, C. – Thorne, C., et al.: Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPARÉ trial. *J Rheumatol*, 2010, 38, s. 1355–1362.
- 24 Foerder, C. – Rogge, M.: Immunogenicity of Enbrel® (etanercept): clinical trial observations. Prezentováno na Annual European Congress of Rheumatology, Stockholm, Švédsko, 2002, abstrakt THU0032, s. 12–15.
- 25 Jani, M. – Chinoy, H. – Warren, R. B., et al.: Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. *Lancet*, 2015, 26, s. 385.
- 26 Jamnitski, A. – Kriekaert, C. L. – Nurmohamed, M. T., et al.: Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. *Ann Rheum Dis*, 2012, 71, s. 88–91.
- 27 Arstikyte, I. – Kapleryte, G. – Butrimiene, I., et al.: Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNF α Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients. *Biomed Res Int*, 2015, 2015, s. 604–872.
- 28 de Vries, M. K. – van der Horst-Bruinsma, I. E. – Nurmohamed, M. T., et al.: Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. *Ann Rheum Dis*, 2009, 68, s. 531–535.

Bolest u osteoartrózy kolene dospělých – novinky v léčbě

Mgr. Dana Frantálová

- 1 Bolten, W. – Glade, M. J. – Raum, S. – Ritz, B. W.: The safety and efficacy of an enzyme combination in managing knee osteoarthritis pain in adults: a randomized, double-blind, placebo-controlled trial. *Arthritis*, 2015, Epub 31. 1. 2015, www.ncbi.nlm.nih.gov/pubmed/25802756.

Stroncium ranelát – efektívna možnosť liečby osteoporózy

prof. MUDr. Juraj Payer, PhD., MPH, FRCP | MUDr. Peter Jackuliak, PhD. |

MUDr. Kristína Brázdilová, PhD. V. interná klinika Lekárskej fakulty UK a UN, Bratislava

- 1 Payer, J. – Killinger, Z., et al.: Stroncium ranelát. In: *Osteoporóza*. Bratislava, Herba, 2012, s. 210–211.
- 2 Khosla, S.: Minireview. OPG/RANK/RANKL system. *Endocrinology*, 2001, 142, s. 5050–5055.
- 3 Kaygili, O. – Keser, S. – Kom, M., et al.: Strontium substituted hydroxyapatites: Synthesis and determination of their structural properties, in vitro and in vivo performance. *Mater Sci Eng C Mater Biol Appl*, 2015, 55, s. 538–546.
- 4 Bruyere, O. – Roux, C. – Detilleux, J., et al.: Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. *J Clin Endocrinol Metab*, 2007, 92, s. 3076–3081.
- 5 Payer, J. – Vaňuga, P. – Tomková, S., et al.: Treatment of the postmenopausal osteoporosis by strontium ranelate in every-day practice – DUAL study. *Osteopor Int*, 2010, 21, s. S226.
- 6 Masaryk, P. – Letkovská, A. – Rovenský, J.: Stroncium ranelát – nové dôkazy účinnosti. *Rheumatol*, 2011, 2, s. 78–84.
- 7 Donneau, A. F. – Reginster, J. Y.: Cardiovascular safety of strontium ranelate: real-life assessment in clinical practice. *Osteoporos Int*, 2014, 25, s. 397–398.
- 8 Jenšovský, J.: Stroncium ranelát – dôležitá alternatíva v liečbe osteoporózy. *Farmakoterapie*, 2015, 11, s. 385–450.
- 9 Odborné usmernenie MZ SR pre diagnostiku a liečbu osteoporózy. *Vestník MZ SR*, 2006, 54, s. 9–16.
- 10 Watts, N. B. – Diab D. I.: Long-term use of bisphosphonates in osteoporosis. *J Clin Endocrinol Metab*, 2010, 95, s. 1555–1565.
- 11 Cooper, C. – Reginster, J. Y. – Cortet, B., et al.: Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). *Curr Med Res Opin*, 2012, 28, s. 475–491.
- 12 Odborné usmernenie MZ SR pre diagnostiku a liečbu glukokortikoidmi indukovanej osteoporózy. *Vestník MZ SR*, 2009, 57, s. 51–53.
- 13 Jobke, B. – Burghardt, A. J. – Mueche, B., et al.: Trabecular reorganization in consecutive iliac crest biopsies when switching from bisphosphonate to strontium ranelate treatment. *PLoS One*, 2011, 6, s. e23638.
- 14 Arlot, M. E. – Jiang, Y. – Genant, H. K., et al.: Histomorphometric and uCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. *J Bone Miner Res*, 2008, 23, s. 215–222.
- 15 Horák, P. – Skácelová, M.: Miesto stroncium ranelátu v liečbe osteoporózy. *Interní Med*, 2015, 17, s. 87–90.

Co môžeme urobiť pro pacienta s psoriatickou artritídou, když selžou inhibitory TNF α ?

MUDr. Jiří Štolfa Revmatologický ústav, Praha

- 1 Gossec, L. – Smolen, J. S. – Gaujoux-Viala, C., et al.: European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. *Ann Rheum Dis*, 2012, 71, s. 4–12.
- 2 Nielsen, O. H. – Bukhave, K. – Elmgreen, J., et al.: Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid. *Dig Dis Sci*, 1987, 32, s. 577–582.
- 3 Nash, P. – Thaci, D. – Behrens, F., et al.: Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. *Dermatology*, 2006, 212, s. 238–249.
- 4 Mease, P. J. – Armstrong, A. W.: Managing patients with psoriatic arthritis: The diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. *Drugs*, 2014, 74, s. 423–441.
- 5 Kristensen, E. L. – Golfe, A. – Saxne, T. – Geborek P.: Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. *Ann Rheum Dis*, 2008, 67, s. 364–369.
- 6 Hsu, L. – Snoggrass, B. T. – Armstrong, A. W.: Antidrug antibodies in psoriasis: a systematic review. *Br J Dermatol*, 2014, 170, s. 261–273.
- 7 Bito, T. Z. – Nishikava, R. – Hatakeyama, M., et al.: Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis. *Br J Dermatol*, 2014, 170, s. 922–929.
- 8 Mok, C. C. – van der Kleij, D. – Wolbink, G. J.: Drug levels, anti-drug antibodies, and clinical efficacy of anti-TNF α biologics in rheumatic diseases. *Clin Rheumatol*, 2013, 32, s. 1429–1435.
- 9 Zisapel, M. – Zisman, D. – Madar-Balakirski, N., et al.: Prevalence of TNF- α blocker immunogenicity in psoriatic arthritis. *J Rheumatol*, 2015, 42, s. 73–78.
- 10 Fagerli, K. M. – Lie, E. – van der Heijde, D., et al.: The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. *Ann Rheum Dis*, 2014, 73, s. 132–137.
- 11 Karanikolas, G. N. – Kouklj, E. M. – Katsalira, A. Q., et al.: Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial. *J Rheumatol*, 2011, 38, s. 2466–2474.
- 12 Fagerli, K. M. – Lie, E. – van der Heijde, D., et al.: Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study. *Ann Rheum Dis*, 2013, 72, s. 1840–1844.
- 13 Glinthborg, G. – Ostergard, M. – Krogh, N. S., et al.: Clinical response, drug survival and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: Results from the Danish Nationwide DANBIO Registry. *Arthritis Rheum*, 2013, 65, s. 1213–1223.
- 14 van der Neijde, D. – Fleischmann, R. – Wollenhaupt, J., et al.: Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID- α 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol. *Ann Rheum Dis*, 2014, 73, s. 233–237.
- 15 Ritchlin, C. T. – Gottlieb, A. B. – McInnes, I. B., et al.: Ustekinumab in active psoriatic arthritis including patients previously treated with anti-TNF agents: results of a phase 3, multicenter, double-blind, placebo-controlled study [abstrakt 2557]. *Arthritis Rheum*, 2012, 64 (dopl.), s. S1080–S1081.
- 16 Ritchlin, C. – Rahman, P. – Kavanaugh, A., et al.: PSUMMIT 2 Study Group. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicenter, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. *Ann Rheum Dis*, 2014, 73, s. 990–999.
- 17 Noordenbos, T. – Yerenko, N. – Gofita, I., et al.: Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. *Arthritis Rheum*, 2012, 64, s. 99–109.
- 18 McInnes, I. B. – Mease, P. J. – Kirkham, B., et al.: FUTURE 2 Study Group. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*, 2015.
- 19 Fleischmann, R. – Kremer, J. – Cush, J., et al.: Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. *N Engl J Med*, 2012, 367, s. 495–507.
- 20 Ghoreschi, K. – Laurinca, A. – O'Shia, J. J.: Janus kinases in immune cell signaling. *Immunol Rev*, 2009, 228, s. 273–287.
- 21 Papp, K. A. – Menter, A. – Strober, B., et al.: Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled doseranging study. *Br J Dermatol*, 2012, 167, s. 668–677.
- 22 Schafer, P. H. – Parton, A. – Sandhi, A. K., et al.: Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. *Br J Pharmacol*, 2010, 159, s. 842–855.
- 23 Schett, G. – Wollenhaupt, J. – Papp, K., et al.: Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. *Arthritis Rheum*, 2012, 64, s. 3156–3167.
- 24 Kavanaugh, A. – Mease, P. J. – Gomez-Reino, J. J., et al.: Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results of a phase 3, randomized, controlled trial [abstrakt L13]. *Arthritis Rheum*, 2012, 64, s. 4172–4173.
- 25 Celgene International Sarl. Apremilast achieves statistical significance for the primary endpoint of the first phase III study (PALACE-1) in patients with psoriatic arthritis. Tisková zpráva; 2012.
- 26 Mease, P. – Genovese, M. C. – Gladstein, G., et al.: Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomised, double-blind, placebo controlled, Phase II trial. *Arthritis Rheum*, 2011, 63, s. 939–948.
- 27 Kavanaugh, A., et al.: Maintenance of clinical efficacy and radiographic benefit through 2 years of ustekinumab therapy in patients with active psoriatic arthritis: Results from the PSUMMIT 1 trial. *Arthritis Care Res (Hoboken)*, 19. 6. 2015, doi: 10.1002/acr.22645.

Revmatologické projevy u pacientů s mukopolysacharidózou

MUDr. RNDr. Pavel Ješina, Ph.D. Ústav dědičných metabolických poruch 1. LF UK a VFN, Praha

- 1 Poupátová, H. – Ledvinová, J. – Berná, L., et al.: The birth prevalence of lysosomal disorders in the Czech Republic: comparison with data in different populations. *J Inher Metab Dis*, 2010, 33, s. 387–396.
- 2 Morishita, K. – Petty, R. E.: Musculoskeletal manifestations of mucopolysaccharidosis. *Rheumatology*, 2011, 50, s. 19–25.
- 3 Wraith, J. E. – Scarpa, M. – Ceck, M., et al.: Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. *Eur J Pediatr*, 2008, 167, s. 267–277.
- 4 Ješina, P. – Magner, M. – Poupátová, H., et al.: Mukopolysacharidóza I – klinické projevy u 24 dětí z české republiky a Slovenska. *Čes-slov Pediatr*, 2011, 66, s. 6–11.
- 5 Montano, A. M. – Tomatu, S. – Gottesman, G. S., et al.: International Morquio A registry: clinical manifestation and natural course of Morquio A disease. *J Inher Metab Dis*, 2007, 30, s. 165–174.
- 6 Valstar, M. J. – Neijls, S. – Bruggenwirth, H. Z., et al.: Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations. *Ann Neurol*, 2010, 68, s. 876–887.
- 7 Coutinho, M. F. – Lacerda, L. – Alves, S.: Glycosaminoglycan storage disorders: A review. *Biochem Res Int*, 2012, 471325, doi: 10.1155/2012/471325.
- 8 Lehman, T. J. A. – Miller, N. – Norquist, B., et al.: Diagnosis of the mucopolysaccharidoses. *Rheumatology*, 2011, 50, s. 41–48.
- 9 Valayannopoulos, V. – Wijburg, F. A.: Therapy for the mucopolysaccharidoses. *Rheumatology*, 2011, 50, s. 49–59.